Compare Carvana Co (CVNA) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Heron Therapeutics Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Carvana Co is far larger — about 1022.6× Heron Therapeutics Inc's market cap, and Carvana Co is more actively traded (7,671,750 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Heron Therapeutics Inc for 35 Days on average.
| CVNA | HRTX | |
|---|---|---|
Market Cap | $69.55B | $68.01M |
Volume | 7,671,750 | 1,891,941 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $1.49 |
52-Week Low | $56.27 | $0.27 |
Typical Hold Time | 28 Days | 35 Days |
Enterprise Value | $72.04B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.73, up 1.55% today, showing strong fundamental momentum with revenue surging to $20.32B in 2025 and net income reaching $1.41B. The stock has consistently beaten earnings expectations in recent quarters, though technical indicators signal bearish pressure with key resistance at $64-65. Recent news highlights Carvana as the 'best story' in autos with September sales beating estimates by 40%.
Carvana presents a compelling growth story with expanding profitability and aggressive capacity expansion, though high debt levels and volatile technical signals warrant caution. Analyst consensus targets $84.07 (32% upside) with 46% buy ratings, but investors face execution risks from inventory constraints and competitive pressures in the used car market.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
